8.5 Extension to dual, triple-agonist and amylin-based co-agonist therapies The emergence of dual and multi-agonist therapies, such as the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide, raises important questions regarding the generalisability of the proposed framework
In short, GLP-1 RA users had longer diabetes duration, higher prevalence of obesity, and higher prevalence of previous use of insulins and sulfonylureas than those in the DPP-4i group
Experimental gut procedure may help stop weight regain after GLP-1 drugs GLP1 drugs commonly cause digestive side effects but may have wider benefits Most weight lost on GLP-1 drugs returns within a year after stopping There are other possible explanations too
Fewer Side Effects Nausea, fatigue, and GI discomfort are dose-dependent
Lifestyle Habits Semaglutide works best when it is combined with a healthy lifestyle including a balanced diet and regular exercise
Research explores its potential influence on mitochondrial function and adaptive cellular responses
